15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $386M | -$19M | 71.3% | -3.7% | $1M | — | $89M |
| 2024 | $602M | $2M | 73.8% | 0.5% | $17M | — | $91M |
| 2023 | $1.1B | $99M | 72.4% | 11.8% | $141M | — | $94M |
| 2022 | $1.6B | $144M | 71.3% | 11.6% | $178M | — | $88M |
| 2021 | $1.5B | $164M | 73.9% | 14.2% | $60M | — | $104M |
| 2020 | — | $103M | — | — | $139M | — | $164M |
| 2019 | — | $78M | — | — | $74M | — | $77M |
| 2018 | — | $56M | — | — | $56M | — | $81M |
| 2017 | — | $28M | — | — | $40M | — | $75M |
| 2016 | — | $18M | — | — | $22M | — | $52M |
| 2015 | — | $20M | — | — | $27M | — | $42M |
| 2014 | — | $13M | — | — | $19M | — | $24M |
| 2013 | — | $24M | — | — | $31M | $0 | $36M |
| 2012 | — | $16M | — | — | $32M | $3M | $40M |
| 2011 | — | $19M | — | — | $21M | $4M | $14M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $76M | -$2M | 68.1% | -4.3% | -$836000 | — | $72M |
| Dec '25 | $75M | -$18M | 69.4% | -10.4% | -$7M | — | $89M |
| Sep '25 | $89M | -$2M | 69.5% | -4.6% | $11M | — | $100M |
| Jun '25 | $106M | $2M | 72.6% | -1.0% | -$5M | — | $102M |
| Mar '25 | $116M | -$772000 | 72.8% | -1.1% | $2M | — | $92M |
| Dec '24 | $119M | $801000 | 74.1% | 0.6% | -$7M | — | $91M |
| Sep '24 | $140M | $1M | 75.4% | 1.5% | $8M | — | $115M |
| Jun '24 | $169M | -$8M | 73.2% | -4.7% | $11M | — | $108M |
| Mar '24 | $175M | $8M | 72.8% | 4.5% | $5M | — | $97M |
| Dec '23 | $191M | $6M | 74.0% | 4.5% | $10M | — | $94M |
| Sep '23 | $236M | $23M | 75.2% | 10.8% | $28M | — | $113M |
| Jun '23 | $296M | $30M | 71.1% | 13.1% | $41M | — | $147M |
| Mar '23 | $349M | $40M | 70.6% | 15.3% | $62M | — | $124M |
| Dec '22 | $337M | $27M | 69.3% | 9.7% | $43M | — | $88M |
| Sep '22 | $390M | $36M | 72.5% | 12.3% | $54M | — | $70M |
| Jun '22 | $453M | $39M | 71.0% | 10.8% | $41M | — | $61M |
| Mar '22 | $418M | $42M | 72.4% | 13.2% | $41M | — | $118M |
| Dec '21 | — | $34M | — | — | -$19M | — | $104M |
| Sep '21 | — | $42M | — | — | $5M | — | $155M |
| Jun '21 | — | $47M | — | — | $13M | — | $192M |
How the market has priced MED against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, MEDIFAST INC's revenue has declined 29.1% per year. These are computed facts, not advice.
As of FY2025, MEDIFAST INC reported — of total debt against $89M of cash.
In FY2025, gross margin was 71.3%, operating margin -3.7%, and net margin -4.9%.
As of Jun '26, MEDIFAST INC traded at a price-to-earnings ratio of about 61.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.